Welcome back to The Pause Collective Science Review, where I read the science so you don't have to. This was a big week. The American College of Physicians - one of the largest physician organizations in the United States - published a new guideline that says, clearly and at the top of the page, that hormone therapy should be the first treatment offered for bothersome hot flashes and night sweats. We also have an important long-term PMOS study that separates what body weight explains from what it does not, a practical guide in a major medical journal on what the PMOS name change means in the exam room, and a small but interesting trial of an oral, non-hormonal option for vaginal dryness and discomfort. Then, as always, what is actually trending - and how it holds up against the evidence.
1. A landmark guideline: the American College of Physicians says hormone therapy comes first for hot flashes
What it is. On October 6, the American College of Physicians (ACP) published a new clinical guideline on drug treatment for menopausal vasomotor symptoms - hot flashes and night sweats, which affect up to 80% of women around menopause. The guideline was built on a formal systematic review and meta-analysis and used the GRADE framework, the strictest standard for rating how certain the evidence is. An editorial by Drs. Regina Castaneda and Stephanie Faubion (past president of The Menopause Society) accompanied it.
What it recommends. For women seeking treatment for hot flashes and night sweats, ACP strongly recommends - on high-certainty evidence of net benefit:
First-line: estrogen plus progestogen for women with a uterus, or estrogen alone for women without a uterus.
Second-line (for women who cannot take or do not tolerate estrogen): an SNRI antidepressant - venlafaxine or desvenlafaxine.
Third-line: an SSRI (escitalopram or paroxetine), gabapentin, or one of the newer neurokinin receptor antagonists (fezolinetant or elinzanetant).
ACP also asks clinicians to bring up hot flashes themselves, because many women never do, and to choose treatment through shared decision-making that weighs benefits, harms, contraindications, other conditions, cost, and access.
What this means in plain English. For more than two decades after the Women's Health Initiative, many women and many doctors treated hormone therapy as a last resort. This guideline is the clearest statement yet from a major mainstream physician group that the evidence points the other way for most women with bothersome symptoms: hormone therapy is not the fallback. It is the first thing that should be offered, with non-hormonal medications as genuine, evidence-backed alternatives for women who cannot or do not want to use it. It also quietly legitimizes the newer non-hormonal drugs - fezolinetant and elinzanetant now sit inside a major guideline's recommended pathway.
The limits. The guideline covers hot flashes and night sweats only. It does not tell any individual woman which dose, form, or duration is right for her, and it does not apply to women with specific contraindications - that remains a personal conversation with your doctor. The evidence base is thinnest for women who cannot take estrogen and for the newest agents. And a guideline is a map, not a guarantee: what matters is how it changes the conversation in your own exam room.
For our PMOS readers. If you have PMOS, menopause is coming for you too, one day. It is worth knowing now what good care is supposed to look like when you get there - a doctor who asks about your symptoms and starts with the treatment that has the strongest evidence. The standard of care is being written in your favor.
Sources: Qaseem A, Mackey K, Yost J, et al. Pharmacologic Treatments for Females With Menopausal Vasomotor Symptoms: A Clinical Guideline From the American College of Physicians. Ann Intern Med. 2026. doi:10.7326/ANNALS-26-01205. Supporting systematic review: Diem S, Drake T, Kaka AS, et al. Ann Intern Med. 2026. doi:10.7326/ANNALS-26-00943. Editorial: Castaneda R, Faubion SS. Ann Intern Med. 2026. doi:10.7326/ANNALS-26-03184. ACP press release, October 5, 2026: https://www.acponline.org/acp-newsroom/acp-recommends-hormonal-therapy-as-a-first-line-treatment-for-menopausal-vasomotor-symptoms
2. Lean versus overweight PMOS, followed for years: weight raises the risk - but it does not create it
What it studied. A retrospective cohort of 1,500 women with Rotterdam-defined PMOS (500 lean, 1,000 overweight or obese) at a tertiary reproductive medicine center in China, enrolled between December 2020 and May 2022 and followed through December 2025 - a median of 4.3 years. The two main outcomes were new-onset metabolic syndrome and, in the subgroup going through fertility treatment (973 women, 1,432 IVF cycles), the cumulative live-birth rate.
What it found. Overweight and obese women fared worse on nearly every measure: new metabolic syndrome in 19.94% versus 9.22% of lean women (adjusted hazard ratio 2.33), new type 2 diabetes in 7.0% versus 2.6%, and a cumulative live-birth rate of 52.84% versus 70.49% (adjusted odds ratio 0.46 - roughly half the odds of taking home a baby). Pregnancy complications were also more common: gestational diabetes 23.49% versus 10.06%, hypertensive disorders of pregnancy 9.44% versus 2.83%, and macrosomia (very large babies) 11.65% versus 4.40%.
But the sentence in this paper that matters most is this one: lean PMOS was not metabolically benign. Nearly one in ten lean women developed metabolic syndrome in just over four years, and 2.6% developed type 2 diabetes - despite a normal BMI and far lower insulin resistance at baseline.
What this means in plain English. If you have PMOS and a higher body weight, this study says weight-stratified metabolic monitoring and structured pre-pregnancy weight care are worth real effort - the risk gap is large and it shows up in fertility outcomes, not just blood tests. And if you are lean with PMOS, do not let a normal BMI talk anyone - including your doctor - out of checking your metabolic health. PMOS is a metabolic condition at every size.
The limits. This is a retrospective, single-center study in Chinese women - BMI cutoffs and metabolic risk thresholds differ across populations, and a fertility-clinic population is not the average woman with PMOS. The live-birth outcome only applies to the IVF subgroup. Retrospective designs can show association, not prove cause. The findings fit the wider evidence (insulin resistance in PMOS exists independent of BMI), which strengthens them, but they should be read as one well-done cohort, not the final word.
For our menopause readers. This is why we say PMOS is a lifelong metabolic condition, not a fertility problem you age out of. The women in this study are heading toward perimenopause carrying this metabolic risk with them - and menopause adds its own cardiometabolic pressure on top. If you have a PMOS history and you are in your forties, your metabolic screening should not stop just because your periods did. This is exactly the handoff between the two halves of our community.
Source: Wen J, Guo R, Zuo Z. Metabolic and reproductive outcomes in lean versus overweight/obese phenotypes of polyendocrine metabolic ovarian syndrome: a retrospective cohort study with long-term follow-up. BMC Endocr Disord. 2026. doi:10.1186/s12902-026-02575-6. (Note: the journal page was not directly reachable this week; findings above are from the published abstract and indexing records.)
3. The PMOS name change reaches the clinic: CMAJ tells doctors how to actually use it
What it is. CMAJ, the Canadian Medical Association Journal - one of the most widely read general medical journals in the world - published a practice article on October 5 explaining the new PMOS name and, more importantly, what clinicians should do differently because of it.
What it says. The old name, PCOS, implied that ovarian cysts are the defining problem, that ultrasound is central to diagnosis, and that reproduction is the main concern. All three implications are wrong or incomplete. The article's practical advice: during the transition, clinicians should say "PMOS, formerly PCOS"; previous diagnoses remain valid and the diagnostic criteria have not changed; every patient should get baseline metabolic screening at diagnosis, with cardiometabolic risk factors rechecked every 1 to 3 years; and doctors should be careful that the word "metabolic" is not heard by patients as a coded comment about weight - insulin resistance in PMOS exists independent of body mass index, and surveillance is about prevention, not judgment.
What this means in plain English. The rename has now moved out of consensus documents and into the journals your family doctor actually reads. Expect the vocabulary in your exam room and your chart to shift before anything about your actual diagnosis does - and expect (or ask for) the metabolic conversation to come earlier and more often.
The limits. This is an educational practice article, not new data. Its job is to change habits, which takes years. We covered the rename itself, and the evidence behind it, in my four-part series earlier this fall - this is the implementation chapter, and it is worth watching.
Source: Mills G. Polyendocrine metabolic ovarian syndrome: a new name to support better treatment. CMAJ. 2026;198(34):E1341-E1342. doi:10.1503/cmaj.261239. https://www.cmaj.ca/content/198/34/E1341
4. A pill for vaginal dryness? A small trial of oral hyaluronic acid
What it studied. Genitourinary syndrome of menopause (GSM) - vaginal dryness, burning, discomfort with sex, urinary irritation - is common, chronic, and undertreated. This exploratory open-label trial randomized 60 postmenopausal women with vulvovaginal atrophy into three groups for 60 days: an oral full-spectrum sodium hyaluronate supplement, a vaginal hyaluronic acid ovule, or both combined.
What it found. Vaginal Health Index scores - a clinician-rated measure of vaginal tissue health - improved significantly in all three groups by day 30 and again by day 60. At day 60, the combination group scored highest, and the oral supplement alone outperformed the vaginal ovule alone. Patient-reported symptoms improved across the board, most in the oral and combination groups.
What this means in plain English. Hyaluronic acid is the same moisture-binding molecule used in skin care, and taken by mouth it appears to reach vaginal tissue. For women who cannot or do not want to use local estrogen, an oral, non-hormonal option that showed measurable benefit - especially combined with a local treatment - is genuinely interesting.
The limits. Be honest with yourself about what this is: 60 women, 60 days, no placebo group, everyone knew what they were taking, and it tested one specific commercial formulation. Symptom trials without a placebo tend to flatter the treatment. This is a promising signal that justifies a proper blinded trial - not a reason to replace standard care, which remains vaginal estrogen or other proven GSM treatments.
Source: Governini L, Vicariotto F, De Leo V, Nobile V. Oral full-spectrum sodium hyaluronate for vulvovaginal atrophy in postmenopausal women: a randomized, parallel-group clinical trial. Nutr J. 2026. doi:10.1186/s12937-026-01404-9. (Note: findings are from the published abstract; the full journal page was not directly reachable this week.)
What is trending - and how it holds up
The ACP guideline is the menopause story of the week. Coverage in Healio, MedPageToday, and ACP's own newsroom (all October 5) has been, for once, largely accurate: "hormone therapy first for hot flashes" is what the guideline actually says. Expect this to dominate menopause social media for days. Where I would add caution: the headline applies to hot flashes and night sweats in women without contraindications. It is not a blanket "everyone should take hormones," and it says nothing about hormones for brain fog, weight, or anti-aging. (Grounded: ACP newsroom, Healio, MedPageToday coverage.)
The world menopause congress just wrapped. The International Menopause Society's 20th World Congress ran September 29 to October 3 in Rio de Janeiro. The headline-making item out of it: Astellas presented preliminary real-world data from its Phase 4 OPTION-VMS study of fezolinetant (VEOZAH), reporting improvement in bothersome hot flashes by week 12 and better sleep - including an average of 2.6 fewer nighttime awakenings per night at week 12, measured both by questionnaires and by a medical-grade wearable. Sleep disturbance affects an estimated 40-60% of menopausal women, so the interest is understandable. The honest caveats: this is a company press release about a preliminary analysis, the study was not designed to compare fezolinetant against other treatments, and real-world improvement from baseline is not the same as proof of superiority. Still, objective sleep data from wearables is a welcome step beyond questionnaires. (Grounded: imsociety.org and imsrio2026.com for the congress; the Astellas/PRNewswire release of October 2 for the data.)
The PMOS rename keeps rolling. This week the story reached CMAJ (annotated above), a Medscape primary-care explainer (October 5), and further science-media coverage. On r/PCOS, the community debate is real and unresolved: the May announcement thread drew thousands of upvotes, while a July thread titled "Am I the only one who hates the new PMOS name?" captured the other side - some women hear "PMOS" as too close to "PMS," and worry it will be used to dismiss them. Both things can be true: the name is more accurate, and transitions are uncomfortable. My take, as I wrote in the rename series: use "PMOS, formerly PCOS," and keep the patient at the center. (Grounded: the cited articles and publicly visible Reddit threads via search; I did not browse Reddit directly this week.)
What your TikTok feed is and is not showing you. A study published September 29 in the journal Menopause analyzed 834 videos from the 10 most influential menopause creators on TikTok. Sexual symptoms were rarely mentioned - vaginal dryness in 3.5% of videos, libido changes in 7.9%, pain with sex in 2.0% - while mood changes (31.2%) and hot flashes (13.5%) dominated. Half the videos (51.6%) were about validating symptoms or empowerment, 19.3% offered management strategies, and 13.2% included product endorsements. Only 1 of the 10 most influential creators was a medical professional. Validation matters - feeling believed is not nothing. But if your feed is where you learn about menopause, you are seeing an incomplete picture that skews away from sexual health and toward whoever has the biggest following. (Grounded: Hariharan L, Ahsan SJ, Rowen TS. Menopause. 2026. doi:10.1097/gme.0000000000002938. I did not browse TikTok directly; this is the published analysis.)
One to file under "the press caught up." Canadian media (CTV News / The Canadian Press, October 1) covered how women's physical and mental health can worsen after menopause in type 1 diabetes. That is the BETTER registry analysis we annotated in last week's review - good to see it getting the attention it deserves. And Sunnybrook's October 1 press release on blood markers linking menopause and brain aging is the Nature Medicine proteomics study we covered in Issue 5; the science is the same, the headlines are new.
A note on method, as always: the trending items above are grounded in news coverage, press releases, and publicly visible discussion threads found through search. Where I have not browsed a platform directly, I say so, and where something is my interpretation rather than a fact, I mark it as such.
That is the week in science. The big picture: mainstream medicine is moving, visibly, toward taking both menopause symptoms and PMOS as seriously as they deserve - a first-line hormone therapy recommendation from America's internists, metabolic screening woven into the PMOS name change, and a global congress paying attention to sleep. We will keep reading. You keep asking questions.
Until next time,
Dr. Herman Weiss
Medical Disclaimer
The information provided in this blog post and newsletter is for educational and informational purposes only. It does not constitute medical advice or professional services and should not be used to diagnose or treat any health problem or disease. Always seek the advice of your physician or other qualified health-care provider regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read here. Use of this content does not create a doctor-patient relationship. Individual responses to treatments and lifestyle changes can vary, and only your healthcare provider can evaluate your specific circumstances. If you are experiencing a medical emergency, call your local emergency services immediately.
